# US 2020/0392252 A1 · Anti-talen antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392252 A1
- Document ID: US20200392252A1
- Status: Published application
- Kind: A1
- Application number: 16/900,602
- Filed: 2020-06-12
- Published: 2020-12-17
- Earliest claimed: 2019-06-13
- Assignees: Allogene Therapeutics, Inc.
- Applicants: Allogene Therapeutics, Inc.
- Inventors: Thomas Charles PERTEL; Barbra Johnson SASU
- Web page: https://patentgrep.com/patent/US20200392252A1

## CPC

- C07K 16/40: against enzymes
- C40B 40/08: Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
- G01N 33/532: Production of labelled immunochemicals
- G01N 33/6854: {Immunoglobulins}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure provides, among other things, antibodies for detecting TALENs and/or FokI nucleases in a sample and methods of using the same.

## Claims

### Claim 1

An anti-TALEN antibody comprising a variable heavy chain amino acid sequence that is at least 85% identical to SEQ ID NO: 3 and a variable light chain amino acid sequence that is at least 85% identical to SEQ ID NO: 7, wherein the anti-TALEN antibody optionally is humanized.

### Claim at position 2

2-3. (canceled)

### Claim 4 (depends on 1)

The anti-TALEN antibody of claim 1, wherein the antibody comprises one or more of the following:
(a) a variable heavy chain (HC) selected from the group consisting of SEQ ID NOs: 3-6,
(b) a heavy chain CDR1 selected from the group consisting of SEQ ID NOs: 12-14,
(c) a heavy chain CDR2 selected from the group consisting of SEQ ID NOs: 15-20,
(d) a heavy chain CDR3 comprising SEQ ID NO: 21,
(e) a heavy chain that comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3, each CDR comprising an amino acid sequence shown in Table 1c
(f) a light chain variable region (VL) sequence selected from the group consisting of SEQ ID NOs: 7-11.

### Claim at position 4

5-8. (canceled)

### Claim 9 (depends on 4)

An anti-TALEN antibody comprising a VH amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a VH of an antigen binding molecule of claim 4, or a VL amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a light chain variable region (VL) sequence selected from the group consisting of SEQ ID NOs: 7-11.

### Claim 10

(canceled)

### Claim 11 (depends on 4)

The anti-TALEN antibody of claim 4 comprising a light chain variable region (VL) sequence selected from the group consisting of SEQ ID NOs: 7-11, further comprising one of the following:
(a) a light chain CDR1 comprising SEQ ID NOs: 22,
(b) a light chain CDR2 selected from the group consisting of SEQ ID NO: 23-25,
(c) a light chain CDR3 selected from the group consisting of SEQ ID NOs: 26-28
(d) a light chain CDR1, a light chain CDR2 and a light chain CDR3, each CDR comprising an amino acid sequence in Table 1d.

### Claim at position 8

12-15. (canceled)

### Claim 16

An anti-TALEN antibody, comprising
(a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:12;
(b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15;
(c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21;
(d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22;
(e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 23; and
(f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 26,
and optionally
(g) a VH comprising the amino acid sequence of SEQ ID NO: 3; and
(h) a VL comprising the amino acid sequence of SEQ ID NO: 7,
or comprising
(i) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12;
(j) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 16;
(k) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21;
(l) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22;
(m) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and
(n) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 27,
and optionally
(o) a VH comprising the amino acid sequence of SEQ ID NO: 3; and
(p) a VL comprising the amino acid sequence of SEQ ID NO: 8,
or comprising
(q) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 13;
(r) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 16;
(s) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21;
(t) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22;
(u) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 25; and
(v) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 26,
and optionally
(w) a VH comprising the amino acid sequence of SEQ ID NO: 4; and
(x) a VL comprising the amino acid sequence of SEQ ID NO: 9,
or comprising
(y) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12;
(z) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15;
(aa) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21;
(bb) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22;
(cc) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and
(dd) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 28,
and optionally
(ee) a VH comprising the amino acid sequence of SEQ ID NO: 5; and
(ff) a VL comprising the amino acid sequence of SEQ ID NO: 10,
or comprising
(gg) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12;
(hh) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 17;
(ii) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21;
(jj) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22;
(kk) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and
(ll) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 27,
and optionally
(mm) a VH comprising the amino acid sequence of SEQ ID NO: 6; and
(nn) a VL comprising the amino acid sequence of SEQ ID NO: 11,
or comprising
(oo) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12;
(pp) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15;
(qq) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21;
(rr) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22;
(ss) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and
(tt) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 27,
and optionally
(uu) a VH comprising the amino acid sequence of SEQ ID NO: 3; and
(vv) a VL comprising the amino acid sequence of SEQ ID NO: 8,
or comprising
(ww) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12;
(xx) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 16;
(yy) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21;
(zz) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22;
(aaa) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 25; and
(bbb) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 26,
and optionally
(ccc) a VH comprising the amino acid sequence of SEQ ID NO: 4; and
(ddd) a VL comprising the amino acid sequence of SEQ ID NO: 9.

### Claim at position 10

17-29. (canceled)

### Claim 30 (depends on 1)

The anti-TALEN antibody of claim 1, wherein the isolated antibody further comprises a detectable label.

### Claim 31 (depends on 30)

The anti-TALEN antibody of claim 30, wherein the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, and a hapten.

### Claim 32 (depends on 31)

The anti-TALEN antibody of claim 31, wherein the fluorescent label is selected from the group consisting of an Atto dye, an Alexafluor dye, quantum dots, Hydroxycoumarin, Aminocouramin, Methoxycourmarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-Phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cerulean, mCFP, mTurquoise2, ECFP, CyPet, GFP (Y66W mutation), mKeima-Red, TagCFP, AmCyanl, mTFP1, GFP (S65A mutation), Midorishi Cyan, Wild Type GFP, GFP (S65C mutation), TurboGFP, TagGFP, GFP (S65L mutation), Emerald, GFP (S65T mutation), EGFP, Azami Green, ZsGreenl, TagYFP, EYFP, Topaz, Venus, mCitrine, YPet, TurboYFP, ZsYellowl, Kusabira Orange, mOrange, Allophycocyanin (APC), mKO, TurboRFP, tdTomato, TagRFP, DsRed monomer, DsRed2 (“RFP”), mStrawberry, TurboFP602, AsRed2, mRFP1, J-Red, R-phycoerythrin (RPE), B-phycoeryhring (BPE), mCherry, HcRedl, Katusha, P3, Peridinin Chlorophyll (PerCP), mKate (TagFP635), TurboFP635, mPlum, and mRaspberry.

### Claim 33 (depends on 32)

The anti-TALEN antibody of claim 32, wherein the fluorescent label is R-Phycoerythrin (PE) or Allophycocyanin (APC).

### Claim 34 (depends on 1)

A composition comprising the anti-TALEN antibody of claim 1 and a pharmaceutically acceptable carrier or vehicle.

### Claim 35 (depends on 1)

A polynucleotide encoding the heavy chain of an anti-TALEN antibody of claim 1.

### Claim 36 (depends on 1)

A polynucleotide encoding the light chain of an anti-TALEN antibody of claim 1.

### Claim 37 (depends on 1)

A vector comprising a polynucleotide encoding the heavy chain or the light chain of an anti-TALEN antibody of claim 1.

### Claim 38 (depends on 1)

A cell comprising one or both of the vectors selected from the group consisting of a vector comprising a polynucleotide encoding the heavy chain of an anti-TALEN antibody of claim 1 and a vector comprising a polynucleotide encoding the light chain of an anti-TALEN antibody of claim 1.

### Claim 39 (depends on 38)

The cell of claim 38, wherein the cell comprises a cell selected from the group consisting of a CHO cell, a Sp2/0 cell, a rabbit cell and an E. coli cell.

### Claim 40 (depends on 1, 39)

A method of making an anti-TALEN antibody of claim 1 comprising incubating the cell of claim 39 under suitable conditions.

### Claim 41

A method of determining the presence or absence of a TALEN protein in a sample, comprising contacting the sample with an anti-TALEN antibody conjugated to a detectable label and determining the presence or absence of the TALEN protein in the sample.

### Claim 42 (depends on 1, 41)

The method of claim 41, wherein the anti-TALEN antibody comprises an antibody of claim 1 or a humanized form thereof.

### Claim 43 (depends on 41)

The method of claim 41, wherein the sample is an immune cell, a tissue sample, a blood sample, a formalin-fixed sample, a tissue grown ex vivo or cell culture media.

### Claim 44 (depends on 42)

The method of claim 42, wherein the sample is an immune cell, a tissue sample, a blood sample, a formalin-fixed sample, a tissue grown ex vivo or cell culture media.
